Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Autoimmune Disorders

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 185 articles:
HTML format
Text format



Single Articles


    September 2017
  1. VILLANI S, Zanotta N, Ambrogi F, Comar M, et al
    Multiplex array analysis of circulating cytokines and chemokines in natalizumab-treated patients with multiple sclerosis.
    J Neuroimmunol. 2017;310:91-96.
    PubMed     Text format     Abstract available


  2. CHANGYALEKET B, Deliu Z, Chignalia AZ, Feinstein DL, et al
    Heparanase: Potential roles in multiple sclerosis.
    J Neuroimmunol. 2017;310:72-81.
    PubMed     Text format     Abstract available


  3. JAHAN I, Ahammad RU, Farzana KS, Khalid MM, et al
    Tumor necrosis factor-alpha -863C/A polymorphism is associated with Guillain-Barre syndrome in Bangladesh.
    J Neuroimmunol. 2017;310:46-50.
    PubMed     Text format     Abstract available


  4. NIELSEN BR, Ratzer R, Bornsen L, von Essen MR, et al
    Characterization of naive, memory and effector T cells in progressive multiple sclerosis.
    J Neuroimmunol. 2017;310:17-25.
    PubMed     Text format     Abstract available


  5. HAITAO R, Huiqin L, Tao Q, Xunzhe Y, et al
    Autoimmune encephalitis associated with vitiligo?
    J Neuroimmunol. 2017;310:14-16.
    PubMed     Text format     Abstract available


  6. DELGADO-GARCIA G, Corona-Vazquez T
    IgG4-related disease and IgG4-mediated neurological autoimmune disorders: One and the same?
    J Neuroimmunol. 2017;310:129-130.
    PubMed     Text format    


  7. PENN M, Mausner-Fainberg K, Golan M, Karni A, et al
    High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;310:120-128.
    PubMed     Text format     Abstract available


    August 2017
  8. LISAK RP, Nedelkoska L, Benjamins JA, Schalk D, et al
    B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.
    J Neuroimmunol. 2017;309:88-99.
    PubMed     Text format     Abstract available


  9. WALLWITZ U, Brock S, Schunck A, Wildemann B, et al
    From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum.
    J Neuroimmunol. 2017;309:77-81.
    PubMed     Text format     Abstract available


  10. PITAROKOILI K, Kohle F, Motte J, Fatoba O, et al
    Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis.
    J Neuroimmunol. 2017;309:58-67.
    PubMed     Text format     Abstract available


  11. DEMARSHALL C, Goldwaser EL, Sarkar A, Godsey GA, et al
    Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
    J Neuroimmunol. 2017;309:51-57.
    PubMed     Text format     Abstract available


  12. CAROTENUTO A, Scalia G, Ausiello F, Moccia M, et al
    CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    J Neuroimmunol. 2017;309:47-50.
    PubMed     Text format     Abstract available


  13. MATHEY EK, Garg N, Park SB, Nguyen T, et al
    Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies.
    J Neuroimmunol. 2017;309:41-46.
    PubMed     Text format     Abstract available


  14. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Cytomegalovirus and varicella zoster virus seropositivity of Iranian patients with multiple sclerosis: A population-based study.
    J Neuroimmunol. 2017;309:4-6.
    PubMed     Text format     Abstract available


  15. BETTENCOURT A, Boleixa D, Guimaraes AL, Leal B, et al
    The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population.
    J Neuroimmunol. 2017;309:34-37.
    PubMed     Text format     Abstract available


  16. PIERI M, Storto M, Pignalosa S, Zenobi R, et al
    KFLC Index utility in multiple sclerosis diagnosis: Further confirmation.
    J Neuroimmunol. 2017;309:31-33.
    PubMed     Text format     Abstract available


    July 2017
  17. YOSHIKURA N, Kimura A, Hayashi Y, Inuzuka T, et al
    Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2017 Jul 19. pii: S0165-5728(17)30144.
    PubMed     Text format     Abstract available


    June 2017
  18. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Text format     Abstract available


  19. ASMAIL A, Kesler A, Drory VE, Kolb H, et al
    Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel.
    J Neuroimmunol. 2017;307:47-52.
    PubMed     Text format     Abstract available


  20. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Text format     Abstract available


  21. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Text format     Abstract available


  22. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Text format     Abstract available


  23. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Text format     Abstract available


  24. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Text format     Abstract available


    May 2017
  25. JING S, Song Y, Song J, Pang S, et al
    Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
    J Neuroimmunol. 2017 May 30. pii: S0165-5728(17)30074.
    PubMed     Text format     Abstract available


  26. AKAISHI T, Nakashima I, Mugikura S, Aoki M, et al
    Whole brain and grey matter volume of Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2017;306:68-75.
    PubMed     Text format     Abstract available


  27. SISAY S, Lopez-Lozano L, Mickunas M, Quiroga-Fernandez A, et al
    Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    J Neuroimmunol. 2017;306:40-45.
    PubMed     Text format     Abstract available


  28. CONSTANTINESCU R, Krysl D, Andren K, Asztely F, et al
    Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.
    J Neuroimmunol. 2017;306:25-30.
    PubMed     Text format     Abstract available


  29. BERMUDEZ-MORALES VH, Fierros G, Lopez RL, Martinez-Nava G, et al
    Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults.
    J Neuroimmunol. 2017;306:20-24.
    PubMed     Text format     Abstract available


  30. RAMAKRISHNAN V, Akram Husain RS, Ahmed SS
    Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis.
    J Neuroimmunol. 2017;306:11-18.
    PubMed     Text format     Abstract available


  31. SELMAJ I, Mycko MP, Raine CS, Selmaj KW, et al
    The role of exosomes in CNS inflammation and their involvement in multiple sclerosis.
    J Neuroimmunol. 2017;306:1-10.
    PubMed     Text format     Abstract available


    April 2017
  32. RAIBAGKAR P, Ferry JA, Stone JH
    Is MuSK myasthenia gravis linked to IgG4-related disease?
    J Neuroimmunol. 2017;305:82-83.
    PubMed     Text format     Abstract available


  33. MORIGUCHI K, Miyamoto K, Kusunoki S
    4-Aminopyridine ameliorates experimental autoimmune neuritis in Lewis rats.
    J Neuroimmunol. 2017;305:72-74.
    PubMed     Text format     Abstract available


  34. JACOB S, Al-Kandari A, Alroughani R, Al-Temaimi R, et al
    Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.
    J Neuroimmunol. 2017;305:5-8.
    PubMed     Text format     Abstract available


  35. BUTTARI F, Zagaglia S, Marciano L, Albanese M, et al
    TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;305:172-174.
    PubMed     Text format     Abstract available


  36. BROWN MP, Hissaria P, Hsieh AH, Kneebone C, et al
    Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy.
    J Neuroimmunol. 2017;305:16-18.
    PubMed     Text format     Abstract available


  37. ZHANG M, Liu RT, Zhang P, Zhang N, et al
    Parthenolide inhibits the initiation of experimental autoimmune neuritis.
    J Neuroimmunol. 2017;305:154-161.
    PubMed     Text format     Abstract available


  38. ADAMCZYK-SOWA M, Bieszczad-Bedrejczuk E, Galiniak S, Rozmilowska I, et al
    Oxidative modifications of blood serum proteins in myasthenia gravis.
    J Neuroimmunol. 2017;305:145-153.
    PubMed     Text format     Abstract available


  39. MIFFLIN KA, Frieser E, Benson C, Baker G, et al
    Voluntary wheel running differentially affects disease outcomes in male and female mice with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2017;305:135-144.
    PubMed     Text format     Abstract available


  40. MUTO M, Mori M, Liu J, Uzawa A, et al
    Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
    J Neuroimmunol. 2017;305:131-134.
    PubMed     Text format     Abstract available


  41. MASUDA H, Mori M, Uchida T, Uzawa A, et al
    Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:102-107.
    PubMed     Text format     Abstract available


  42. WANG Q, Xing C, Hao Y, Shi Q, et al
    Memory B cells in Guillain-Barre syndrome.
    J Neuroimmunol. 2017;305:1-4.
    PubMed     Text format     Abstract available


    February 2017
  43. DEPAULA-SILVA AB, Hanak TJ, Libbey JE, Fujinami RS, et al
    Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.
    J Neuroimmunol. 2017 Feb 12. pii: S0165-5728(16)30480.
    PubMed     Text format     Abstract available


    January 2017
  44. NAKAHARA K, Nakane S, Nakajima M, Yamashita S, et al
    Effect of thymectomy for thymic atrophy in myasthenia gravis: A retrospective study on 93 patients.
    J Neuroimmunol. 2017 Jan 12. pii: S0165-5728(16)30355.
    PubMed     Text format     Abstract available


    December 2016
  45. ALVARENGA-FILHO H, Salles M, Hygino J, Ferreira TB, et al
    Fatigue favors in vitro Th1 and Th17-like cell expansion and reduces corticoid sensitivity in MS patients.
    J Neuroimmunol. 2016 Dec 30. pii: S0165-5728(16)30393.
    PubMed     Text format     Abstract available


  46. ANNUNZIATA P, Cioni C, Mugnaini C, Corelli F, et al
    Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
    J Neuroimmunol. 2016 Dec 23. pii: S0165-5728(16)30274.
    PubMed     Text format     Abstract available


  47. PAOLICELLI D, Manni A, D'Onghia M, Direnzo V, et al
    Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    J Neuroimmunol. 2016 Dec 21. pii: S0165-5728(16)30371.
    PubMed     Text format     Abstract available


  48. MATUTE-BLANCH C, Rio J, Villar LM, Midaglia L, et al
    Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 18. pii: S0165-5728(16)30310.
    PubMed     Text format     Abstract available


  49. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Text format     Abstract available


  50. GORDON-LIPKIN E, Calabresi PA
    Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 14. pii: S0165-5728(16)30447.
    PubMed     Text format     Abstract available


  51. HOSSAIN MJ, Tanasescu R, Gran B
    Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2.
    J Neuroimmunol. 2016 Dec 13. pii: S0165-5728(16)30448.
    PubMed     Text format     Abstract available


  52. MOMCILOVIC M, Stamenkovic V, Jovanovic M, Andjus PR, et al
    Tenascin-C deficiency protects mice from experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016 Dec 7. pii: S0165-5728(16)30207.
    PubMed     Text format     Abstract available


    November 2016
  53. HAGHMORAD D, Mahmoudi MB, Salehipour Z, Jalayer Z, et al
    Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 26. pii: S0165-5728(16)30423.
    PubMed     Text format     Abstract available


  54. PROKOPOVA B, Hlavacova N, Vlcek M, Penesova A, et al
    Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis.
    J Neuroimmunol. 2016 Nov 19. pii: S0165-5728(16)30241.
    PubMed     Text format     Abstract available


  55. ACHIRON A, Zilkha-Falb R, Mashiach R, Gurevich M, et al
    RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30209.
    PubMed     Text format     Abstract available


  56. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Angiogenic factors are associated with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30304.
    PubMed     Text format     Abstract available


  57. ZHANG Y, Liu G, Duan Y, Han X, et al
    Prevalence of Small Intestinal Bacterial Overgrowth in Multiple Sclerosis: a Case-Control Study from China.
    J Neuroimmunol. 2016 Nov 16. pii: S0165-5728(16)30187.
    PubMed     Text format     Abstract available


  58. HAITAO R, Yingmai Y, Yan H, Fei H, et al
    Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy.
    J Neuroimmunol. 2016;300:9-10.
    PubMed     Text format     Abstract available


  59. MURIS AH, Smolders J, Rolf L, Thewissen M, et al
    Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study.
    J Neuroimmunol. 2016;300:47-56.
    PubMed     Text format     Abstract available


  60. DIAS-CARNEIRO RP, von Glehn F, Moraes AS, Boldrini VO, et al
    MRZH reaction increases sensitivity for intrathecal IgG synthesis in IgG Oligoclonal band negative Multiple Sclerosis patients.
    J Neuroimmunol. 2016;300:30-35.
    PubMed     Text format     Abstract available


  61. GUASP M, Sola-Valls N, Martinez-Hernandez E, Gil MP, et al
    Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67).
    J Neuroimmunol. 2016;300:15-17.
    PubMed     Text format     Abstract available


  62. KALINOWSKA-LYSZCZARZ A, Michalak S, Pawlak MA, Losy J, et al
    Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis.
    J Neuroimmunol. 2016;300:11-14.
    PubMed     Text format     Abstract available


  63. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Text format     Abstract available


  64. IWASA K, Furukawa Y, Yoshikawa H, Yamada M, et al
    Caveolin-3 is aberrantly expressed in skeletal muscle cells in myasthenia gravis.
    J Neuroimmunol. 2016 Nov 9. pii: S0165-5728(16)30378.
    PubMed     Text format     Abstract available


  65. LV Z, Shi Q, Huang W, Xing C, et al
    MicroRNA expression profiling in Guillain-Barre syndrome.
    J Neuroimmunol. 2016 Nov 4. pii: S0165-5728(16)30374.
    PubMed     Text format     Abstract available


  66. HAAS J, Schwarz A, Korporal-Kuhnke M, Jarius S, et al
    Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 2. pii: S0165-5728(16)30258.
    PubMed     Text format     Abstract available


  67. AHARONI R, Rosen C, Shezen E, Bar-Lev DD, et al
    Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 1. pii: S0165-5728(16)30381.
    PubMed     Text format     Abstract available


    October 2016
  68. SAMUKAWA M, Kuwahara M, Morikawa M, Ueno R, et al
    Electrophysiological assessment of Guillain-Barre syndrome with both Gal-C and ganglioside antibodies; tendency for demyelinating type.
    J Neuroimmunol. 2016 Oct 24. pii: S0165-5728(16)30348.
    PubMed     Text format     Abstract available


  69. MELIEF J, Koper JW, Endert E, Moller HJ, et al
    Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis.
    J Neuroimmunol. 2016;299:84-89.
    PubMed     Text format     Abstract available


  70. FENOGLIO C, De Riz M, Pietroboni AM, Calvi A, et al
    Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
    J Neuroimmunol. 2016;299:81-83.
    PubMed     Text format     Abstract available


  71. DA COSTA DS, Hygino J, Ferreira TB, Kasahara TM, et al
    Vitamin D modulates different IL-17-secreting T cell subsets in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:8-18.
    PubMed     Text format     Abstract available


  72. PULIDO MA, DerHartunian MK, Qin Z, Chung EM, et al
    Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.
    J Neuroimmunol. 2016;299:70-78.
    PubMed     Text format     Abstract available


  73. BETTINI M, Gonorazky H, Chaves M, Fulgenzi E, et al
    Immune-mediated rippling muscle disease and myasthenia gravis.
    J Neuroimmunol. 2016;299:59-61.
    PubMed     Text format     Abstract available


  74. BRIKEN S, Rosenkranz SC, Keminer O, Patra S, et al
    Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2016;299:53-58.
    PubMed     Text format     Abstract available


  75. WANG J, Zhao C, Kong P, Bian G, et al
    Methylene blue alleviates experimental autoimmune encephalomyelitis by modulating AMPK/SIRT1 signaling pathway and Th17/Treg immune response.
    J Neuroimmunol. 2016;299:45-52.
    PubMed     Text format     Abstract available


  76. JONS D, Kneider M, Fogelstrand L, Jeppsson A, et al
    Early hematopoiesis in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:158-163.
    PubMed     Text format     Abstract available


  77. DOOLEY MM, de Gannes SL, Fu KA, Lindsey JW, et al
    The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins.
    J Neuroimmunol. 2016;299:147-151.
    PubMed     Text format     Abstract available


  78. WALLER R, Woodroofe MN, Wharton SB, Ince PG, et al
    Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role.
    J Neuroimmunol. 2016;299:139-146.
    PubMed     Text format     Abstract available


  79. ZHANG F, Liu G, Bu Y, Ma X, et al
    Expression profile of long noncoding RNAs and mRNAs in peripheral blood mononuclear cells from myasthenia gravis patients.
    J Neuroimmunol. 2016;299:124-129.
    PubMed     Text format     Abstract available


  80. MANE-MARTINEZ MA, Olsson B, Bau L, Matas E, et al
    Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    J Neuroimmunol. 2016;299:112-117.
    PubMed     Text format     Abstract available


  81. LIM JA, Lee ST, Moon J, Jun JS, et al
    New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2.
    J Neuroimmunol. 2016;299:107-111.
    PubMed     Text format     Abstract available


  82. MAGGI P, Sati P, Massacesi L
    Magnetic resonance imaging of experimental autoimmune encephalomyelitis in the common marmoset.
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30306.
    PubMed     Text format     Abstract available


  83. CROSS AH, Song SK
    "A new imaging modality to non-invasively assess multiple sclerosis pathology".
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30328.
    PubMed     Text format     Abstract available


  84. REICH DS
    Imag(in)ing multiple sclerosis: Time to take better pictures.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30307.
    PubMed     Text format     Abstract available


  85. ITOH N, Kim R, Peng M, DiFilippo E, et al
    Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30308.
    PubMed     Text format     Abstract available


    September 2016
  86. BOIOCCHI C, Monti MC, Osera C, Mallucci G, et al
    Heat shock protein 70-hom gene polymorphism and protein expression in multiple sclerosis.
    J Neuroimmunol. 2016;298:189-93.
    PubMed     Text format     Abstract available


  87. TAO Y, Zhang X, Markovic-Plese S
    Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
    J Neuroimmunol. 2016;298:181-8.
    PubMed     Text format     Abstract available


  88. DOURADO ME JUNIOR, Ferreira LC, Freire-Neto FP, Jeronimo SM, et al
    No association between FCGR2A and FCGR3A polymorphisms in Guillain-Barre Syndrome in a Brazilian population.
    J Neuroimmunol. 2016;298:160-4.
    PubMed     Text format     Abstract available


  89. MENG QF, Zhang Z, Wang YJ, Chen W, et al
    Astilbin ameliorates experimental autoimmune myasthenia gravis by decreased Th17 cytokines and up-regulated T regulatory cells.
    J Neuroimmunol. 2016;298:138-45.
    PubMed     Text format     Abstract available


  90. OZGUN-ACAR O, Celik-Turgut G, Gazioglu I, Kolak U, et al
    Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental allergic encephalomyelitis model of multiple sclerosis in C57BL/6 mice.
    J Neuroimmunol. 2016;298:106-16.
    PubMed     Text format     Abstract available


  91. COSENTINO M, Zaffaroni M, Legnaro M, Bombelli R, et al
    Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
    J Neuroimmunol. 2016;298:82-9.
    PubMed     Text format     Abstract available


  92. LEBRUN C, Bourg V, Bresch S, Cohen M, et al
    Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.
    J Neuroimmunol. 2016;298:79-81.
    PubMed     Text format     Abstract available


  93. KARNI A, Asmail A, Drory VE, Kolb H, et al
    Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms.
    J Neuroimmunol. 2016;298:58-62.
    PubMed     Text format     Abstract available


  94. HONG Y, Li HF, Skeie GO, Romi F, et al
    Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients.
    J Neuroimmunol. 2016;298:51-7.
    PubMed     Text format     Abstract available


  95. HORSTMANN L, Kuehn S, Pedreiturria X, Haak K, et al
    Microglia response in retina and optic nerve in chronic experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;298:32-41.
    PubMed     Text format     Abstract available


  96. MIYAZAKI Y, Niino M, Kanazawa I, Suzuki M, et al
    Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
    J Neuroimmunol. 2016;298:24-31.
    PubMed     Text format     Abstract available


  97. EFTHYMIOU G, Dardiotis E, Liaskos C, Marou E, et al
    Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis.
    J Neuroimmunol. 2016;298:19-23.
    PubMed     Text format     Abstract available


  98. TANAKA M, Tanaka K
    Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;298:16-8.
    PubMed     Text format     Abstract available


  99. BERG J, Mahmoudjanlou Y, Duscha A, Massa MG, et al
    The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor.
    J Neuroimmunol. 2016;298:9-15.
    PubMed     Text format     Abstract available


    August 2016
  100. ZHANG Y, Liu G, Han X, Dong H, et al
    The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China.
    J Neuroimmunol. 2016;297:127-31.
    PubMed     Text format     Abstract available


  101. KEIL M, Sonner JK, Lanz TV, Oezen I, et al
    General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation.
    J Neuroimmunol. 2016;297:117-26.
    PubMed     Text format     Abstract available


  102. PUTHENPARAMPIL M, Miante S, Federle L, Zanetta C, et al
    BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset.
    J Neuroimmunol. 2016;297:63-7.
    PubMed     Text format     Abstract available


  103. SHENG JR, Rezania K, Soliven B
    Impaired regulatory B cells in myasthenia gravis.
    J Neuroimmunol. 2016;297:38-45.
    PubMed     Text format     Abstract available


  104. CALA CM, Moseley CE, Steele C, Dowdy SM, et al
    T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis.
    J Neuroimmunol. 2016;297:1-8.
    PubMed     Text format     Abstract available


  105. LOVETT-RACKE AE
    Contribution of EAE to understanding and treating multiple sclerosis.
    J Neuroimmunol. 2016 Aug 12. pii: S0165-5728(16)30195.
    PubMed     Text format     Abstract available


    July 2016
  106. RACKE MK
    Therapeutic developments for autoimmune demyelinating diseases: Musing from an MD (mouse doctor).
    J Neuroimmunol. 2016 Jul 20. pii: S0165-5728(16)30157.
    PubMed     Text format     Abstract available


  107. LEVIN MC, Lee S, Gardner LA, Shin Y, et al
    Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered 'ribostasis' and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30155.
    PubMed     Text format     Abstract available


  108. NIMMAGADDA VK, Makar TK, Chandrasekaran K, Sagi AR, et al
    SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30158.
    PubMed     Text format     Abstract available


  109. VALENZUELA RM, Kaufman M, Balashov KE, Ito K, et al
    Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
    J Neuroimmunol. 2016 Jul 2. pii: S0165-5728(16)30137.
    PubMed     Text format     Abstract available


    June 2016
  110. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    Corrigendum to "An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility" [Journal of Neuroimmunology 290 (2016) 115-118].
    J Neuroimmunol. 2016;295-296:164.
    PubMed     Text format    


  111. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis" [J. Neuroimmunol. 290 (2016 Jan. 15) 66-9].
    J Neuroimmunol. 2016;295-296:163.
    PubMed     Text format    


  112. HUANG Q, Xiao B, Ma X, Qu M, et al
    MicroRNAs associated with the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2016;295-296:148-61.
    PubMed     Text format     Abstract available


  113. ANSARI QESHMI S, Dabbagh F, Borhani Haghighi A, Ghasemi Y, et al
    Bioinformatics evaluation of the possibility of heat shock proteins as autoantigens in multiple sclerosis based on molecular mimicry hypothesis.
    J Neuroimmunol. 2016;295-296:100-21.
    PubMed     Text format     Abstract available


  114. KUCUKERDEN M, Huda R, Tuzun E, Yilmaz A, et al
    MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
    J Neuroimmunol. 2016;295-296:84-92.
    PubMed     Text format     Abstract available


  115. NAKANE S, Higuchi O, Hamada Y, Maeda Y, et al
    Ganglionic acetylcholine receptor autoantibodies in patients with Guillain-Barre syndrome.
    J Neuroimmunol. 2016;295-296:54-9.
    PubMed     Text format     Abstract available


  116. CHEN Y, Xing XW, Zhang JT, Wang RX, et al
    Autoimmune encephalitis mimicking sporadic Creutzfeldt-Jakob disease: A retrospective study.
    J Neuroimmunol. 2016;295-296:1-8.
    PubMed     Text format     Abstract available


    May 2016
  117. RAINE CS
    Multiple sclerosis: The resolving lesion revealed.
    J Neuroimmunol. 2016 May 27. pii: S0165-5728(16)30129.
    PubMed     Text format     Abstract available


  118. CATANZARO G, Pucci M, Viscomi MT, Lanuti M, et al
    Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016;294:32-40.
    PubMed     Text format     Abstract available


  119. HAAS J, Schwarz A, Korporal-Kuhnke M, Faller S, et al
    Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis.
    J Neuroimmunol. 2016;294:18-26.
    PubMed     Text format     Abstract available


  120. ERDUR H, Scholz V, Streitz M, Hammer M, et al
    EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis.
    J Neuroimmunol. 2016;294:14-7.
    PubMed     Text format     Abstract available


  121. ZHAO M, Liu MD, Pu YY, Wang D, et al
    Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
    J Neuroimmunol. 2016;294:6-13.
    PubMed     Text format     Abstract available


  122. RIZZO R, Bortolotti D, Fainardi E, Gentili V, et al
    KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
    J Neuroimmunol. 2016;294:1-5.
    PubMed     Text format     Abstract available


  123. SINGH D, Torbey MT, Schwab JM
    Modifiable denominators of evolving post-stroke-autoimmunity.
    J Neuroimmunol. 2016 May 13. pii: S0165-5728(16)30106.
    PubMed     Text format    


    April 2016
  124. ZHANG M, Li XL, Li H, Wang S, et al
    Activation of the adenosine A2A receptor exacerbates experimental autoimmune neuritis in Lewis rats in association with enhanced humoral immunity.
    J Neuroimmunol. 2016;293:129-36.
    PubMed     Text format     Abstract available


  125. ALVARENGA-FILHO H, Sacramento PM, Ferreira TB, Hygino J, et al
    Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators.
    J Neuroimmunol. 2016;293:91-9.
    PubMed     Text format     Abstract available


  126. RAE W, Burke G, Pinto A
    A study of the utility of azathioprine metabolite testing in myasthenia gravis.
    J Neuroimmunol. 2016;293:82-5.
    PubMed     Text format     Abstract available


  127. YAMOUT B, Karaky NM, Mahfouz RA, Jaber F, et al
    Vitamin D receptor biochemical and genetic profiling and HLA-class II genotyping among Lebanese with multiple sclerosis - A pilot study.
    J Neuroimmunol. 2016;293:59-64.
    PubMed     Text format     Abstract available


  128. BENEDEK G, Zhang J, Bodhankar S, Nguyen H, et al
    Estrogen induces multiple regulatory B cell subtypes and promotes M2 microglia and neuroprotection during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;293:45-53.
    PubMed     Text format     Abstract available


  129. YANG B, Lian Y, Liu Y, Wu BY, et al
    A retrospective analysis of possible triggers of Guillain-Barre syndrome.
    J Neuroimmunol. 2016;293:17-21.
    PubMed     Text format     Abstract available


  130. ZHANG DQ, Jia K, Wang R, Li T, et al
    Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;293:100-4.
    PubMed     Text format     Abstract available


  131. BRILL L, Mandel M, Karussis D, Petrou P, et al
    Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel.
    J Neuroimmunol. 2016;293:65-70.
    PubMed     Text format     Abstract available


  132. SHI Z, Chen H, Lian Z, Liu J, et al
    Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression.
    J Neuroimmunol. 2016;293:54-8.
    PubMed     Text format     Abstract available


  133. AKAISHI T, Nakashima I, Takeshita T, Mugikura S, et al
    Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica.
    J Neuroimmunol. 2016;293:28-33.
    PubMed     Text format     Abstract available


    March 2016
  134. STERGIOU C, Lazaridis K, Zouvelou V, Tzartos J, et al
    Titin antibodies in "seronegative" myasthenia gravis - A new role for an old antigen.
    J Neuroimmunol. 2016;292:108-15.
    PubMed     Text format     Abstract available


  135. MELNIKOV M, Belousova O, Murugin V, Pashenkov capital EM, Cyrillic, et al
    The role of dopamine in modulation of Th-17 immune response in multiple sclerosis.
    J Neuroimmunol. 2016;292:97-101.
    PubMed     Text format     Abstract available


  136. PATIL SA, Bokoliya SC, Nagappa M, Taly AB, et al
    Diagnosis of myasthenia gravis: Comparison of anti-nicotinic acetyl choline receptor antibodies, repetitive nerve stimulation and Neostigmine tests at a tertiary neuro care centre in India, a ten year study.
    J Neuroimmunol. 2016;292:81-4.
    PubMed     Text format     Abstract available


  137. SMOLDERS J, Muris AH, Damoiseaux J
    Immunomodulation by vitamin D in multiple sclerosis: More than IL-17.
    J Neuroimmunol. 2016;292:79-80.
    PubMed     Text format    


  138. MAGNER WJ, Weinstock-Guttman B, Rho M, Hojnacki D, et al
    Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
    J Neuroimmunol. 2016;292:68-78.
    PubMed     Text format     Abstract available


  139. SUN Y, Tian T, Gao J, Liu X, et al
    Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice.
    J Neuroimmunol. 2016;292:58-67.
    PubMed     Text format     Abstract available


  140. BURMAN J, Raininko R, Blennow K, Zetterberg H, et al
    YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:52-7.
    PubMed     Text format     Abstract available


  141. BURMAN J, Svenningsson A
    Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:40-4.
    PubMed     Text format     Abstract available


  142. MARTIRE S, Navone ND, Montarolo F, Perga S, et al
    A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
    J Neuroimmunol. 2016;292:34-9.
    PubMed     Text format     Abstract available


  143. PUNGA T, Bartoccioni E, Lewandowska M, Damato V, et al
    Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.
    J Neuroimmunol. 2016;292:21-6.
    PubMed     Text format     Abstract available


  144. MAKAR TK, Nimmagadda VK, Singh IS, Lam K, et al
    TrkB agonist, 7,8-dihydroxyflavone, reduces the clinical and pathological severity of a murine model of multiple sclerosis.
    J Neuroimmunol. 2016;292:9-20.
    PubMed     Text format     Abstract available


  145. MAUSNER-FAINBERG K, Kolb H, Penn M, Regev K, et al
    Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-beta.
    J Neuroimmunol. 2016;292:93-6.
    PubMed     Text format     Abstract available


    February 2016
  146. FATEMI I, Shamsizadeh A, Ayoobi F, Taghipour Z, et al
    Role of orexin-A in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:101-9.
    PubMed     Text format     Abstract available


  147. HUIJBERS MG, Vink AF, Niks EH, Westhuis RH, et al
    Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.
    J Neuroimmunol. 2016;291:82-8.
    PubMed     Text format     Abstract available


  148. MIYAJI K, Paul F, Shahrizaila N, Umapathi T, et al
    Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases.
    J Neuroimmunol. 2016;291:78-81.
    PubMed     Text format     Abstract available


  149. MATAS E, Bau L, Martinez-Iniesta M, Romero-Pinel L, et al
    MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients.
    J Neuroimmunol. 2016;291:73-7.
    PubMed     Text format     Abstract available


  150. FORWELL AL, Bernales CQ, Ross JP, Yee IM, et al
    Analysis of CH25H in multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2016;291:70-2.
    PubMed     Text format     Abstract available


  151. XIE C, Ciric B, Yu S, Zhang GX, et al
    IL-12Rbeta2 has a protective role in relapsing-remitting experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:59-69.
    PubMed     Text format     Abstract available


  152. MORIGUCHI K, Miyamoto K, Tanaka N, Ueno R, et al
    C-C chemokine receptor type 4 antagonist Compound 22 ameliorates experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:54-8.
    PubMed     Text format     Abstract available


  153. IRELAND SJ, Guzman AA, Frohman EM, Monson NL, et al
    B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses.
    J Neuroimmunol. 2016;291:46-53.
    PubMed     Text format     Abstract available


  154. SHINODA K, Sun X, Oyamada A, Yamada H, et al
    Requirement of CD30 expression on CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;291:39-45.
    PubMed     Text format     Abstract available


  155. MADEIRA A, Burgelin I, Perron H, Curtin F, et al
    MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.
    J Neuroimmunol. 2016;291:29-38.
    PubMed     Text format     Abstract available


  156. ZAHEDNASAB H, Karampoor S
    The correlation of HLA-G with multiple sclerosis.
    J Neuroimmunol. 2016;291:28.
    PubMed     Text format    


  157. BLAIR TC, Manoharan M, Rawlings-Rhea SD, Tagge I, et al
    Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis.
    J Neuroimmunol. 2016;291:1-10.
    PubMed     Text format     Abstract available


  158. ZHANG W, Jiao Y, Cui L, Jiao J, et al
    Differentiation of neuromyelitis optica spectrum disorders from ultra-longitudinally extensive transverse myelitis in a cohort of Chinese patients.
    J Neuroimmunol. 2016;291:96-100.
    PubMed     Text format     Abstract available


    January 2016
  159. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility.
    J Neuroimmunol. 2016;290:115-8.
    PubMed     Text format     Abstract available


  160. KHORRAMDELAZAD H, Bagheri V, Hassanshahi G, Zeinali M, et al
    New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis.
    J Neuroimmunol. 2016;290:70-5.
    PubMed     Text format     Abstract available


  161. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Expression of DNA methylation genes in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;290:66-9.
    PubMed     Text format     Abstract available


  162. ARUMUGAM M, Parthasarathy V
    Reduction of CD4(+)CD25(+) regulatory T-cells in migraine: Is migraine an autoimmune disorder?
    J Neuroimmunol. 2016;290:54-9.
    PubMed     Text format     Abstract available


  163. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: A cross-sectional study.
    J Neuroimmunol. 2016;290:47-8.
    PubMed     Text format     Abstract available


  164. MORENO MA, Burns T, Yao P, Miers L, et al
    Therapeutic depletion of monocyte-derived cells protects from long-term axonal loss in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2016;290:36-46.
    PubMed     Text format     Abstract available


  165. FISCHER HJ, van den Brandt J, Lingner T, Odoardi F, et al
    Modulation of CNS autoimmune responses by CD8(+) T cells coincides with their oligoclonal expansion.
    J Neuroimmunol. 2016;290:26-32.
    PubMed     Text format     Abstract available


  166. SUNWOO JS, Chu K, Byun JI, Moon J, et al
    Intrathecal-specific glutamic acid decarboxylase antibodies at low titers in autoimmune neurological disorders.
    J Neuroimmunol. 2016;290:15-21.
    PubMed     Text format     Abstract available


  167. HASSON T, Kolitz S, Towfic F, Laifenfeld D, et al
    Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
    J Neuroimmunol. 2016;290:84-95.
    PubMed     Text format     Abstract available


  168. MAURER MA, Tuller F, Gredler V, Berger T, et al
    Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
    J Neuroimmunol. 2016;290:49-53.
    PubMed     Text format     Abstract available


    December 2015
  169. SUAREZ-CALVET X, Gallardo E, Illa I
    Comment to "Role of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositis".
    J Neuroimmunol. 2015 Dec 18. pii: S0165-5728(15)30101.
    PubMed     Text format    


  170. FUHLHUBER V, Bick S, Tschernatsch M, Dharmalingam B, et al
    Autoantibody-mediated cytotoxicity in paediatric opsoclonus-myoclonus syndrome is dependent on ERK-1/2 phophorylation.
    J Neuroimmunol. 2015;289:182-6.
    PubMed     Text format     Abstract available


  171. LEE CY, Lam CL, Pang SY, Lau KK, et al
    Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese.
    J Neuroimmunol. 2015;289:177-81.
    PubMed     Text format     Abstract available


  172. LOSHAJ-SHALA A, Regazzoni L, Daci A, Orioli M, et al
    Guillain Barre syndrome (GBS): new insights in the molecular mimicry between C. jejuni and human peripheral nerve (HPN) proteins.
    J Neuroimmunol. 2015;289:168-76.
    PubMed     Text format     Abstract available


  173. SHENG JR, Quan S, Soliven B
    IL-10 derived from CD1d(hi)CD5(+) B cells regulates experimental autoimmune myasthenia gravis.
    J Neuroimmunol. 2015;289:130-8.
    PubMed     Text format     Abstract available


  174. MOHAJERI M, Sadeghizadeh M, Javan M
    Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats.
    J Neuroimmunol. 2015;289:105-10.
    PubMed     Text format     Abstract available


  175. CHAUDHARY P, Marracci G, Galipeau D, Pocius E, et al
    Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model.
    J Neuroimmunol. 2015;289:68-74.
    PubMed     Text format     Abstract available


  176. ALEXOPOULOS H, Kampylafka EI, Fouka P, Tatouli I, et al
    Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease.
    J Neuroimmunol. 2015;289:8-11.
    PubMed     Text format     Abstract available


  177. HORELLOU P, Wang M, Keo V, Chretien P, et al
    Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    J Neuroimmunol. 2015;289:1-7.
    PubMed     Text format     Abstract available


  178. SIUKO M, Valori M, Kivela T, Setala K, et al
    Exome and regulatory element sequencing of neuromyelitis optica patients.
    J Neuroimmunol. 2015;289:139-42.
    PubMed     Text format     Abstract available


  179. YAMOUT BI, Zeineddine MM, Tamim H, Khoury SJ, et al
    Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.
    J Neuroimmunol. 2015;289:93-7.
    PubMed     Text format     Abstract available


  180. KANG H, Cao S, Chen T, Jiang Z, et al
    The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain.
    J Neuroimmunol. 2015;289:56-61.
    PubMed     Text format     Abstract available


    November 2015
  181. TANAKA M, Kinoshita M
    Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity.
    J Neuroimmunol. 2015;288:69.
    PubMed     Text format     Abstract available


  182. ARVIDSSON L, Covacu R, Estrada CP, Sankavaram SR, et al
    Long-distance effects of inflammation on differentiation of adult spinal cord neural stem/progenitor cells.
    J Neuroimmunol. 2015;288:47-55.
    PubMed     Text format     Abstract available


  183. RAMIREZ GA, Lanzani C, Bozzolo EP, Citterio L, et al
    TRPC6 gene variants and neuropsychiatric lupus.
    J Neuroimmunol. 2015;288:21-4.
    PubMed     Text format     Abstract available


    October 2015
  184. MEALY MA, Levy M
    Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.
    J Neuroimmunol. 2015;287:29-30.
    PubMed     Text format     Abstract available


  185. KON T, Nishijima H, Haga R, Funamizu Y, et al
    Hypertrophic pachymeningitis accompanying neuromyelitis optica spectrum disorder: A case report.
    J Neuroimmunol. 2015;287:27-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: